Earnings Call Summary | Belite Bio(BLTE.US) Q1 2024 Earnings Conference
Earnings Call Summary | Belite Bio(BLTE.US) Q1 2024 Earnings Conference
The following is a summary of the Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript:
以下是Belite Bio, Inc（BLTE）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Belite Bio reported Q1 2024 R&D expenses of $6.8 million, a rise from $5.7 million in Q1 2023 due to increased costs for new drug studies and research team expansion.
G&A expenses rose, reaching $1.6 million in Q1 2024 compared to $1.2 million in Q1 2023 primarily due to an increase in share-based compensation.
The company's net loss increased from $6.9 million in Q1 2023 to $7.9 million in Q1 2024.
Belite Bio reported a total of $95.5 million in cash and short-term U.S. Treasury bill investments in Q1 2024, a rise from $77.8 million in Q1 2023 due to funds raised from warrant exercises and follow-on offerings.
Belite Bio報告稱，由於新藥研究和研究團隊擴張的成本增加，2024年第一季度的研發費用爲680萬美元，高於2023年第一季度的570萬美元。
併購支出增加，2024年第一季度達到160萬美元，而2023年第一季度爲120萬美元，這主要是由於基於股份的薪酬增加。
該公司的淨虧損從2023年第一季度的690萬美元增加到2024年第一季度的790萬美元。
Belite Bio報告稱，由於認股權證行使和後續發行籌集的資金，2024年第一季度的現金和短期美國國庫券投資總額爲9,550萬美元，高於2023年第一季度的7,780萬美元。
Business Progress:
業務進展：
The company continued its global Phase 3 trials for Stargardt disease and Geographic Atrophy, reporting positive findings and treatment results.
Belite Bio was granted fast track designation, rare pediatric disease designation, and open drug designation in various territories including the U.S., EU, and Japan.
It maintains several patent families with composition of meta-patents lasting until the 2040s, offering patent protection for the foreseeable future.
The company raised an additional $25 million from a registered rent offering in April and anticipates its cash runway to extend beyond 2026.
Belite Bio's study highlighted promising clinical results, with a higher than anticipated rate of subjects (42%) not converting to atrophic lesions.
該公司繼續進行Stargardt病和地理萎縮的全球3期試驗，報告了積極的發現和治療結果。
Belite Bio在包括美國、歐盟和日本在內的各個地區獲得了快速通道認定、罕見兒科疾病認證和開放藥物認證。
它擁有多個專利家族，其中包含的元專利一直持續到2040年代，爲可預見的將來提供專利保護。
該公司從4月份的註冊租金髮行中又籌集了2500萬美元，預計其現金流將延續到2026年以後。
Belite Bio的研究突顯了令人鼓舞的臨床結果，未轉化爲萎縮性病變的受試者比率（42％）高於預期。
More details: Belite Bio IR
更多詳情： Belite Bio IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。